SCHEMBL23994741

SCHEMBL23994741

COc1ncc(-c2cc(OCc3ccccc3)c3nccn3n2)c(OC)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 4/20 0.41
▸ F2RL3 Q96RI0 1/20 0.40
▸ ATP4A P20648 3/20 0.38
▸ ATP4B P51164 3/20 0.38
▸ FAAH O00519 1/20 0.37
▸ CES1 P23141 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ PDGFRB P09619 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ PDE10A Q9Y233 2/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ PDE2A O00408 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23992878 0.86 SYK (0.38) SYKF2RL3ATP4AATP4BFAAH
SCHEMBL23992853 0.84 SYK (0.40) SYKF2RL3FAAHCES1LMNA
SCHEMBL23993129 0.82 SYK (0.38) SYKF2RL3FAAHCES1LMNA
SCHEMBL23992849 0.82 SYK (0.46) SYK
SCHEMBL23992848 0.81 MTOR (0.39) SYKCYP1A2QPCTQPCTL
SCHEMBL23994516 0.79 SYK (0.36) SYKCYP1A2QPCTQPCTL
SCHEMBL30224642 0.79 SYK (0.36) SYKCYP1A2QPCTQPCTL
SCHEMBL23994841 0.79 SYK (0.36) SYKF2RL3FAAHCES1PDE10A
SCHEMBL23994838 0.79 SYK (0.36) SYKF2RL3FAAHCES1PDE10A
SCHEMBL23994425 0.78 SYK (0.38) SYKCYP1A2QPCTQPCTL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230039553-A1 CD73 COMPOUNDS GILEAD SCIENCES, INC. 2023-02-09 — — US disclosed
WO-2021222522-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039553-A1 CD73 COMPOUNDS ENTPD5, ENTPD1, NT5E SYK 2578/4885F2RL3 3052/4885ATP4A 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback